---
title: "BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston | BMRN Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295412329.md"
description: "BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00 AM ET in Boston. An audio webcast of the presentation will be available live, with an archived version accessible on the company's website for a limited time."
datetime: "2026-08-10T05:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295412329.md)
  - [en](https://longbridge.com/en/news/295412329.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295412329.md)
generator: "portal-rs"
---

# BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston | BMRN Stock News

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.

An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

**About BioMarin**  
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com. 

Contacts:

Investors

Media

*Traci McCarty*

*Marni Kottle*

*BioMarin Pharmaceutical Inc.* 

*BioMarin Pharmaceutical Inc.*

*(415) 455-7558*

*(*650) 374-2803

SOURCE BioMarin Pharmaceutical Inc.

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN](https://longbridge.com/en/news/296092450.md)
- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)
- [BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment](https://longbridge.com/en/news/296376333.md)
- [Eolus schedules webcast, teleconference to present Q2 interim report](https://longbridge.com/en/news/296458713.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**